This Cochrane review update of interventions for the prevention or treatment of medication-relatesd osteonecrosis of the jaw (MRONJ) included 13 RCTs. However the studies provided insufficient to either claim or refute a benefit of the interventions tested for prophylaxis or treatment of MRONJ.
[read the full story...]
This review of the association between non-antiresorptive medications and medication‐related osteonecrosis of the jaw (MRONJ) included 70 studies. A majority of the studies (77%) were case series and the quantity and quality of the evidence is low so the findings should be interpreted cautiously.
[read the full story...]
This review of the the frequency of osteonecrosis of the jaw in bisphosphonate users undergoing dental interventions included 27 studies. having dental procedures of 2.7% (95%CI: 0.9 to 5.2%) being higher in those having dental extractions 4.1% (95%CI: 1.5 to 7.7%).
[read the full story...]
This blog on a review of the efficacy of platelet rich fibrin (PRF) in oral surgery procedures was prepared by MSc Students from @UClanDentistry during a workshop with the @TheDentalElf. The review includes 30 small studies of limited quality more high quality studies are needed to assess effectiveness.
[read the full story...]
This Cochrane review of interventions for the prevention and treatment of medication-related osteonecrosis of the jaw (MRONJ) identified 5 trials. Three were related to prevention and two to treatment providing limited evidence to support interventions. More high quality studies are needed.
[read the full story...]
Thirteen studies were included in this review of medication related osteonecrosis of the jaw. The majority were case series ( 9) with the risk of osteonecrosis after tooth extraction being higher in those taking IV bisphosphonates ( 3.2% (95% CI: 1.7–4.7%) than those on oral bisphosphonates 0.15% (95% CI: 0.0–0.36%).
[read the full story...]
Bisphosphonates (BPs) are used for the treatment of a range of bone problems, e.g., osteoporosis, or bone metastases of malignant cancer. In 2003 the condition of bisphosphonate related osteonecrosis of the jaw (BONJ) was reported. The aim of this retrospective cohort study was to estimate the cumulative incidence and risk ratio for ONJ (osteonecrosis of [read the full story…]
Bisphosphonate-related osteonecrosis of the jaw (BONJ) is a recently recognised condition with reports surfacing in 2003. BONJ defined as exposed, necrotic bone in the maxilla or mandible that has persisted for more than eight weeks in patients taking bisphosphonates and where there has been no history of radiation therapy to the jaw. It has been [read the full story…]
The American Dental Association Center for Evidence-Based Dentistry has just completed a critical review of a paper by Migliorati et al published in 2012 which aimed to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues. This is a growing area of interest but, [read the full story…]
Patients taking bisphosphonates are at increased risk of oral health complications (Bisphosphonate-related Osteonecrosis of the Jaw – BONJ). BONJ is defined as exposed, necrotic bone in the maxilla or mandible that has persisted for more than eight weeks in patients taking bisphosphonates and where there has been no history of radiation therapy to the jaw. Symptoms [read the full story…]
